Scarica l'app Stockscreener
4.89
0.20%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Precedente Chiudi:
$4.88
Aprire:
$4.76
Volume 24 ore:
191.53K
Relative Volume:
1.09
Capitalizzazione di mercato:
$287.04M
Reddito:
$30.91M
Utile/perdita netta:
$-74.28M
Rapporto P/E:
-4.0138
EPS:
-1.2183
Flusso di cassa netto:
$-86.15M
1 W Prestazione:
-0.61%
1M Prestazione:
-16.12%
6M Prestazione:
-2.59%
1 anno Prestazione:
+10.14%
Intervallo 1D:
$4.74
$4.96
Intervallo di 1 settimana:
$4.74
$5.21
Portata 52W:
$2.9448
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Nome
Foghorn Therapeutics Inc
Settore
Industria
Telefono
617-586-3100
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.89 | 287.04M | 30.91M | -74.28M | -86.15M | -1.2183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Ripresa | Jefferies | Buy |
| 2025-12-18 | Iniziato | BTIG Research | Buy |
| 2025-11-07 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Ripresa | B. Riley Securities | Buy |
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Iniziato | B. Riley Securities | Buy |
| 2024-09-03 | Iniziato | Jefferies | Buy |
| 2024-08-19 | Iniziato | Evercore ISI | Outperform |
| 2023-03-28 | Iniziato | BofA Securities | Buy |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-17 | Iniziato | Cowen | Outperform |
| 2020-11-17 | Iniziato | Goldman | Buy |
| 2020-11-17 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-17 | Iniziato | Wedbush | Outperform |
Mostra tutto
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World
Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat
Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - Sahm
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com South Africa
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics (FHTX) maps chromatin-targeting cancer pipeline with Lilly - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Cancer drug developer Foghorn raises $50M, funds work on hard-to-treat tumors - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX) - MarketBeat
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (FH - GuruFocus
Aug Volume: Is Foghorn Therapeutics Inc part of any major index2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Will Foghorn Therapeutics Inc. stock benefit from AI adoptionForecast Cut & Smart Investment Allocation Insights - Naître et grandir
Foghorn Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Should you avoid Foghorn Therapeutics Inc. stock right nowJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday - Defense World
Foghorn Therapeutics (FHTX) grants CFO 400,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) CFO files Form 3 insider ownership - Stock Titan
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - Investing News Network
Foghorn Therapeutics names Ryan Maynard as chief financial officer By Investing.com - Investing.com India
Foghorn Therapeutics Names Veteran Executive as New CFO - The Globe and Mail
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Foghorn Therapeutics names Ryan Maynard as chief financial officer - Investing.com
Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus
Foghorn Therapeutics Appoints Ryan Maynard CFO - marketscreener.com
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Ryan Maynard joins Foghorn Therapeutics (NASDAQ: FHTX) as new CFO - Stock Titan
Foghorn Therapeutics Inc. Announces Executive Changes - marketscreener.com
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.20%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):